273 related articles for article (PubMed ID: 1283856)
41. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
[TBL] [Abstract][Full Text] [Related]
42. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
43. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
44. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Delwail V; Jais JP; Colonna P; Andrieu JM
Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
[TBL] [Abstract][Full Text] [Related]
45. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
[TBL] [Abstract][Full Text] [Related]
46. Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up.
Wiernik PH; Hong F; Glick JH; Bennett JM
Leuk Lymphoma; 2009 Oct; 50(10):1632-41. PubMed ID: 19863338
[TBL] [Abstract][Full Text] [Related]
47. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.
Bossi G; Cerveri I; Volpini E; Corsico A; Baio A; Corbella F; Klersy C; Arico M
Ann Oncol; 1997; 8 Suppl 1():19-24. PubMed ID: 9187424
[TBL] [Abstract][Full Text] [Related]
48. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Fermé C; Mounier N; Casasnovas O; Brice P; Divine M; Sonet A; Bouafia F; Bastard-Stamatoullas A; Bordessoule D; Voillat L; Reman O; Blanc M; Gisselbrecht C;
Blood; 2006 Jun; 107(12):4636-42. PubMed ID: 16478882
[TBL] [Abstract][Full Text] [Related]
49. [Pediatric Hodgkin disease in North Tunisia: clinical and therapeutic study].
Kochbati L; Fdhila F; Belaid I; Rifi H; Barsaoui S; Ben Romdhane N; Bel Hadj Ali Z; Mezlini A; Oubich F; Maalej M
Cancer Radiother; 2012 Oct; 16(7):627-32. PubMed ID: 23084987
[TBL] [Abstract][Full Text] [Related]
50. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
[TBL] [Abstract][Full Text] [Related]
51. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).
Radman I; Basić N; Labar B; Kovacević J; Aurer I; Bogdanić V; Zupancić-Salek S; Nemet D; Jakić-Razumović J; Mrsić M; Santek F; Grgić-Markulin L; Boban D
Ann Oncol; 2002 Oct; 13(10):1650-5. PubMed ID: 12377656
[TBL] [Abstract][Full Text] [Related]
52. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.
Ansell SM
Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486
[TBL] [Abstract][Full Text] [Related]
53. Late relapses in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy.
Salvagno L; Sorarù M; Aversa SM; Bianco A; Chiarion Sileni V; Pappagallo GL; Fiorentino MV
Ann Oncol; 1993 Sep; 4(8):657-62. PubMed ID: 7694635
[TBL] [Abstract][Full Text] [Related]
54. Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital.
Ganesan TS; Oza A; Perry N; D'Ardenne J; Arnott S; Stansfeld AG; Shand WS; Wrigley PF; Lister TA
Ann Oncol; 1992 May; 3(5):349-56. PubMed ID: 1377487
[TBL] [Abstract][Full Text] [Related]
55. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
[TBL] [Abstract][Full Text] [Related]
56. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy.
Carella AM; Prencipe E; Pungolino E; Lerma E; Frassoni F; Rossi E; Giordano D; Occhini D; Gatti AM; Bruni R; Spriano M; Nati S; Pierluigi D; Congiu M; Vimercati R; Ravetti JL; Federico M
Leuk Lymphoma; 1996 Mar; 21(1-2):63-70. PubMed ID: 8907271
[TBL] [Abstract][Full Text] [Related]
57. HIV-related Hodgkin's disease. Report of nine cases.
Novati S; Malfitano A; Sacchi P; Patruno SF; Tornari PM; Rondanelli EG
Haematologica; 1993; 78(1):34-7. PubMed ID: 7684010
[TBL] [Abstract][Full Text] [Related]
58. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
[TBL] [Abstract][Full Text] [Related]
59. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
Noordijk EM; Carde P; Mandard AM; Mellink WA; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Dupouy N
Ann Oncol; 1994; 5 Suppl 2():107-12. PubMed ID: 7515643
[TBL] [Abstract][Full Text] [Related]
60. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
Klimo P; Connors JM
J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
